Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Core Viewpoint - The Ademi Firm is investigating Astria for potential breaches of fiduciary duty related to its transaction with BioCryst, which may not be in the best interest of all shareholders [1][3]. Group 1: Transaction Details - Shareholders of Astria will receive $13.00 per share, consisting of $8.55 in cash and 0.59 shares of BioCryst common stock, indicating an enterprise value of approximately $700 million and an aggregate equity value of $920 million [2]. - The transaction agreement includes provisions that significantly limit competing offers for Astria, imposing a substantial penalty if a competing bid is accepted [3]. Group 2: Investigation Focus - The investigation is centered on the conduct of the Astria board of directors to determine if they are fulfilling their fiduciary duties to all shareholders amidst the transaction with BioCryst [3].